Elena V. Ivanova

Also affiliated with Harvard University, Dana-Farber Cancer Institute

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Targeting TBK1 to overcome resistance to cancer immunotherapy”.

Targeting TBK1 to overcome resistance to cancer immunotherapy

Nature(2023)10.1038/s41586-023-05704-6

N/A

4.0DataRank · unranked

171 citations

Or‐Yam Revach, Seth Anderson, Emily Kessler, Clara Wolfe, Anne Jenney +54 more

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade

Journal of Clinical Investigation(2020)10.1172/jci135038

N/A

1.9DataRank · unranked

75 citations

Andrew Portell, Elena V. Ivanova, Patrick H. Lizotte, Navin R. Mahadevan, Jonathan Greene +23 more

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-1844

N/A

0.564DataRank · unranked

42 citations

Mari Kuraguchi, Man Xu, Andrew Portell, Luke J. Taus, Irmina Diala +17 more

Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.12.019

N/A

0DataRank · unranked

24 citations

Maisam Makarem, Mizuki Nishino, S. Emily Bachert, Tom Zhang, Jaclyn LoPiccolo +11 more

Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome

Blood Advances(2023)10.1182/bloodadvances.2023010531

N/A

0DataRank · unranked

21 citations

Sandra G. Obwar, Anja E. H. Nordstrom, Maria Ericsson, Aisha Saldanha, Elena V. Ivanova +4 more

Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells

Cancers(2023)10.3390/cancers15164128

N/A

0DataRank · unranked

8 citations

Allen Green, Marco Campisi, Minyue Chen, Iliana Gjeci, Navin R. Mahadevan +15 more

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2278

N/A

0DataRank · unranked

124 citations

Melissa L. Johnson, Sarah Clifford, Romel Somwar, Jennifer Kherani, Jieun Son +23 more

Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102198

N/A

0DataRank · unranked

4 citations

Zehua Li, Jessica Ritter, Elliott J. Brea, Navin R. Mahadevan, Deborah Dillon +17 more

Tumor-Derived cGAMP Regulates Activation of the Vasculature

Frontiers in Immunology(2020)10.3389/fimmu.2020.02090

N/A

0DataRank · unranked

61 citations

Shriram K. Sundararaman, Sarah E. Shelton, Erik H. Knelson, Navin R. Mahadevan, Ryohei Yoshida +15 more

Activation of Tumor-Cell STING Primes NK-Cell Therapy

Cancer Immunology Research(2022)10.1158/2326-6066.cir-22-0017

N/A

0DataRank · unranked

89 citations

Elena V. Ivanova, Mubin Tarannum, Marco Campisi, Patrick H. Lizotte, Matthew A. Booker +44 more